NCT05480072View on ClinicalTrials.gov

Endocannabinoids, Stress, Craving And Pain Effects Study

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

January 14, 2025

Study Completion Date

January 14, 2025

Conditions
Opioid Use Disorder
Interventions
DRUG

Palmitoylethanolamide

Palmitoyethanolamide (PEA) s a dietary supplement with anti-inflammatory and analgesic properties. Subjects will receive PEA (Levagen+) 600 capsules mg twice daily (BID) orally from Day 1 to Day 21

OTHER

Placebo

Participants will receive placebo matched to 600 mg PEA (Levagen+) capsules BID orally from Day 1 to Day 21

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER